

CS/NSE/BSE/PR/2016-17
April 4, 2016

To
The Manager
Listing Department
National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla Complex
Bandra (E), Mumbai – 400 051

To
The General Manager
Department of Corporate Services
BSE Limited
25th Floor, P. J. Towers,
Dalal Street, Mumbai - 400 001

Stock Code: SUVEN - EQ

Stock Code: 530239


Dear Sir/Madam,

Sub: Press Release

.....
With reference to above subject, please find enclosed Press Release of our company titled
“**Suven to Present at Bio-Europe Spring 2016 conference being held at Stockholm, Sweden.**”

This is for your information and records.

Thanking you,
Yours faithfully,
For **Suven Life Sciences Limited**


K Hanumantha Rao
Company Secretary

Suven Life Sciences Limited

CIN: L24110TG1989PLC009713

Registered Office: 8-2-334 | SDE Serene Chambers | 6th Floor

Road No.5 | Avenue 7 | Banjara Hills | Hyderabad – 500 034 | Telangana | India

Tel: 91 40 2354 1142/ 3311/ 3315 Fax: 91 40 2354 1152 Email: info@suven.com website: www.suven.com

News Release

Suven to Present at Bio-Europe Spring 2016 conference being held at Stockholm, Sweden

HYDERABAD, INDIA (April 04, 2016) – Several exciting new results and data presentations from Suven's portfolio of investigational neuroscience new chemical entities (NCEs) are being presented at Bio-Europe Spring 2016 in Stockholm, Sweden between April 4-6, 2016.

BIO-Europe Spring® is the premier springtime partnering conference which annually attracts an international "who's who" from biotech, pharma and finance for three days of high caliber networking.

BIO-Europe Spring's partnering ONE®, enables delegates to efficiently identify, meet and get partnerships started with companies across the life science value chain, from large biotech and pharma companies to financiers and innovative start-ups.

During BIO-Europe Spring 2016 partnering conference, Suven lined up several face to face meetings with major Pharma, Biotech and financial companies to explore potential partnering and out licensing of the clinical candidates SUVN-502, SUVN-G3031, SUVN-D4010 and pre-clinical candidate SUVN-911.

Mr.Venkat Jasti is scheduled to discuss the company's corporate overview, business strategy and clinical development pipeline at BIO-Europe Spring 2016 where the world's top notch investment professionals will present along with the most innovative companies who are decision makers.

Suven's near-term focus is to develop the product candidate SUVN-502, for the treatment of Alzheimer's disease and other forms of dementia with the ongoing phase 2a multicenter, randomized, double-blind, parallel group, 26-week, placebo-controlled study of 50 mg and 100 mg of suvn-502 in subjects with moderate Alzheimer's disease currently treated with Donepezil Hydrochloride and Memantine Hydrochloride.

For more information please visit our Web site at <http://www.suven.com>

Risk Statement:

Except for historical information, all of the statements, expectations and assumptions, including expectations and assumptions, contained in this news release may be forward-looking statements that involve a number of risks and uncertainties. Although Suven attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. Other important factors which could cause results to differ materially including outsourcing trends, economic conditions, dependence on collaborative partnership programs, retention of key personnel, technological advances and continued success in growth of sales that may make our products/services offerings less competitive;

Suven Life Sciences Limited

CIN: L24110TG1989PLC009713

Registered Office: 8-2-334 | SDE Serene Chambers | 6th Floor

Road No.5 | Avenue 7 | Banjara Hills | Hyderabad – 500 034 | Telangana | India

Tel: 91 40 2354 1142/ 3311/ 3315 Fax: 91 40 2354 1152 Email: info@suven.com website: www.suven.com